Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study [PDF]
Nevena Vicic +9 more
openalex +1 more source
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. <i>Vaccines</i> 2025, <i>13</i>, 192. [PDF]
Omole T +12 more
europepmc +1 more source
Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
Mencarelli L +8 more
europepmc +1 more source
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar. [PDF]
Chemaitelly H +21 more
europepmc +1 more source
Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine. [PDF]
Scholaert M +12 more
europepmc +1 more source
Adverse events following immunization of mRNA-1273 (Moderna) booster vaccine in clerkship students
Hari Hendarto +4 more
openalex +2 more sources

